 Cytochrome P-450 CYP2D6 Inhibitors
"Cytochrome P-450 CYP2D6 Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP2D6.
| Descriptor ID |
D065690
|
| MeSH Number(s) |
D27.505.389.500.368 D27.505.519.389.335.368
|
| Concept/Terms |
Cytochrome P-450 CYP2D6 Inhibitors- Cytochrome P-450 CYP2D6 Inhibitors
- Cytochrome P 450 CYP2D6 Inhibitors
- P450 CYP2D6 Inhibitors
- CYP2D6 Inhibitors, P450
- Inhibitors, P450 CYP2D6
- CYP2D6 Inhibitors
- Inhibitors, CYP2D6
|
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 CYP2D6 Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 CYP2D6 Inhibitors".
This graph shows the total number of publications written about "Cytochrome P-450 CYP2D6 Inhibitors" by people in this website by year, and whether "Cytochrome P-450 CYP2D6 Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 | | 1999 | 2 | 0 | 2 | | 2002 | 1 | 0 | 1 | | 2014 | 0 | 1 | 1 | | 2018 | 0 | 2 | 2 | | 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cytochrome P-450 CYP2D6 Inhibitors" by people in Profiles.
-
Chapron BD, Dinh JC, Toren PC, Gaedigk A, Leeder JS. The Respective Roles of CYP3A4 and CYP2D6 in the Metabolism of Pimozide to Established and Novel Metabolites. Drug Metab Dispos. 2020 11; 48(11):1113-1120.
-
Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, Symmans WF, McLeod HL, Ratain MJ, Zembutsu H, Gaedigk A, van Schaik RH, Ingle JN, Caudle KE, Klein TE. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clin Pharmacol Ther. 2018 05; 103(5):770-777.
-
Wehry AM, Ramsey L, Dulemba SE, Mossman SA, Strawn JR. Pharmacogenomic Testing in Child and Adolescent Psychiatry: An Evidence-Based Review. Curr Probl Pediatr Adolesc Health Care. 2018 02; 48(2):40-49.
-
Tay-Sontheimer J, Shireman LM, Beyer RP, Senn T, Witten D, Pearce RE, Gaedigk A, Gana Fomban CL, Lutz JD, Isoherranen N, Thummel KE, Fiehn O, Leeder JS, Lin YS. Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics. Pharmacogenomics. 2014 Dec; 15(16):1947-62.
-
Lam YW, Gaedigk A, Ereshefsky L, Alfaro CL, Simpson J. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Pharmacotherapy. 2002 Aug; 22(8):1001-6.
-
Abdel-Rahman SM, Marcucci K, Boge T, Gotschall RR, Kearns GL, Leeder JS. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine. Drug Metab Dispos. 1999 Jul; 27(7):770-5.
-
Abdel-Rahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL. Investigation of terbinafine as a CYP2D6 inhibitor in vivo. Clin Pharmacol Ther. 1999 May; 65(5):465-72.
-
Kashuba AD, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Rocci ML, Kulawy RW, Beck DJ, Bertino JS. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin Pharmacol Ther. 1998 Sep; 64(3):257-68.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|